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level (Figure 1) with hypertelorism and a supernumerary bone at 
the frontal level. Th e fetus showed a small thorax at the expense of 
cervical kyphosis and dorsal level scoliosis (Figure 2) with subjective 
narrowing of the medullar canal. We also found suspicion of blad-
der exstrophy and a bivascular umbilical cord. Suspecting a chro-
mosomal anomaly and/or craniosynostosis, an amniocentesis was 
carried out for a karyotype test and to perform a genetic molecular 
craniosynostosis study  – this was sent to the fetal Medicine Refer-
ence Unit at San Cecilio Hospital (Granada, Spain) for counselling 
and second opinion, which confi rmed our ultrasound diagnosis. 
Th e genetic test revealed a normal karyotype and the technical array 
showed heterozygosity of the c870    T mutation (p.Trp 290Cys) in 
the FGFR2 gene, compatible with Type II Pfeiff er syndrome. 
 Because of the poor prognosis, the patient decided on a termina-
tion of the pregnancy with an anatomopathological study, which 
confi rmed the prenatal fi ndings. 
 Discussion 
 Th e prenatal diagnosis of cranial deformities (Park et  al. 1996) is 
associated with diverse syndromes: a strawberry-shaped cranium 
is associated with trisomy 18 (T18); a lemon-shaped cranium with 
neural tube defects; frontal prominence with achondroplasia and the 
Russell – Silver syndrome; trigonocephaly with Jacobsen  syndrome; 
brachycephaly with trisomy 21 (T21); chondrodysplasia, the  Cornelia 
de Lange syndrome and cranial asymmetry with amniotic band 
 syndrome and the Wolf – Hirschhorn syndrome. A cloverleaf-shaped 
cranium is present in thanatophoric dysplasia (not associated with 
craniosynostosis); or syndromes that indeed are associated with 
craniosynostosis such as Apert, Carpenter, Crouzon, Jackson Weiss 
and Pfeiff er syndromes (Benacerraf et  al. 2000). 
 Pfeiff er syndrome was fi rst described by Pfeiff er in 1964 (Park 
et  al. 1996) and then by Cohen in 1993, based on phenotype severity, 
describing three types: Type I, Type II and Type III. Type I is associ-
 
 Figure 1. Deformation of the cranial bone structure. 
 
 Figure 2. Cervical kyphosis and dorsal level scoliosis. 
ated with mild manifestations, having normal neurological develop-
ment and a good prognosis. Type II comprises a cloverleaf-shaped 
cranium, severe proptosis, arm and feet abnormalities and severely 
compromised neurological development. Type III is similar to Type 
II but without the cloverleaf-shaped cranium (Oyamada et  al. 2003). 
Th e grave neurological deterioration, together with the severe visceral 
manifestations of Type II and Type III generally lead to death within 
the fi rst few years of life (Lee et  al. 2010). 
 Even although the ultrasound analysis makes us suspect the 
pathology, there are incomplete syndromes (as in this case, no 
observed hand and feet deformities), thus it is the genetic analy-
sis which gives the diagnosis. Apert, Crouzon, Jackson Weiss and 
Pfeiff er syndromes are associated with the mutation of fi broblast 
growth factor receptor 1 (FGFR1 on chromosome 8) and fi broblast 
growth factor receptor 2 (FGFR2 on chromosome 10) (Gripp et  al. 
1998). Pfeiff er syndrome Type I is a dominant autosomal inheritance 
mutation in either FGFR1 or FGFR2; whereas Types II and III are 
sporadic mutations in FGFR2 (Piccione et  al. 2009); these mutations 
have been associated with the elevated age of the parents, especially 
of the father, since these mutations appear to off er a selective advan-
tage for sperm survival (Goriely et  al. 2003). Nevertheless, the risk of 
the following child having the syndrome is minimal and the descen-
dents of the patient aff ected by this condition have a 50 – 60% chance 
of transmitting it to their descendents, given the dominant character 
of this gene. 
 Conclusion 
 Prenatal diagnosis of cranial malformations, with suspected premature 
fusion of the sutures, should raise suspicion of Pfeiff er syndrome  – a 
diagnosis that can be confi rmed by genetic testing. 
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Introduction 
 Mitochondrial toxicity induced by inhibition of gamma DNA 
polymerase is an adverse eff ect of nucleoside reverse transcriptase 
inhibitors (NRTI) and is responsible for a broad spectrum of 
clinical conditions that include lactic acidosis and hepatic steatosis 
(Brinkman et  al. 1998). Growing data suggest increased susceptibil-
ity during pregnancy (Fleischer et  al. 2004). Moreover, fatal cases 
have been reported during the 3rd trimester and with long-term 
therapy (Luzzati et  al. 1999; Sarner and Fakoya 2002; Bristol-Myers 
Squibb 2001). Hence, the combination of stavudine and didanosine 
is currently not recommended throughout gestation (Bristol-Myers 
Squibb 2001; AIDS  info 2012). 
 We report a case of an HIV-1-infected pregnant woman present-
ing in the 1st trimester, with symptoms suggesting lactic acidosis 
and who had been on stavudine and lamivudine for only 5 months. 
 Case report 
 A 27-year-old HIV-1-infected nulliparous woman presented with 
vomiting, nausea, asthenia and anorexia in the 10th week of preg-
nancy. She had been on antiretroviral (ARV) therapy since the age 
of 22. At 3 months before pregnancy, and because her viral load was 
rising, she was switched to stavudine, lamivudine and lopinavir/
ritonavir. At the time of conception, she had a CD4 count of 641    10 6 /l 
and an undetectable viral load (   50 copies/ml). On admission, 
examination revealed apyrexia, and a normal pulse and respiratory 
rate. Th ere were no focal signs of hepatitis, pancreatitis or obstetric 
complications. Investigations showed an AST 21 times the upper 
limit of the norm (ULN); ALT 13.5 times the ULN; an elevated GGT 
and LDH (7.5 and 5    ULN, respectively) and a metabolic acidosis 
(pH    7.32), with low bicarbonate (HCO 3 ) and elevated arterial 
lactate (2.5    ULN) (Table I). Abdominal ultrasound and other tests 
were in the normal range. She was managed with the diagnosis of 
lactic acidosis and liver dysfunction probably secondary to NRTI. 
 ARV therapy was immediately stopped. She was managed with 
close surveillance, monitoring gasometry and lactate levels, daily. 
Th e patient was symptom free within 3 days and discharged aft er 
15 days in hospital, during which time investigations gradually 
returned to normal (Table I). Viral load increased to 175.190 copies/
ml and CD4 dropped to 221    10 6 /l. 
 ARV therapy was restarted 4 weeks later, using zidovudine, lami-
vudine and lopinavir/ritonavir. Subsequently, AST and ALT remained 
within the normal range throughout the rest of the pregnancy 
and viral load decreased, becoming undetectable before delivery. An 
elective caesarean section was performed at 38 weeks and 3 days. 
Th e apparently healthy infant was also given zidovudine, according 
to hospital protocol. DNA PCR HIV tests were negative at 48 hours 
and 2, 4, 6 and 12 months aft er birth. 
 Discussion 
 Th e incidence of NRTI-induced lactic acidosis/hepatic steatosis in 
HIV-infected pregnant women is unknown. Nevertheless, there 
are three reported cases of maternal death related to stavudine 
and didanosine use, two associated with fetal death (Bristol-Myers 
Squibb 2001; Sarner and Fakoya 2002). Non-fatal cases with this 
combination have also been described (Mandelbrot et  al. 2003). 
Th ere is also a reported case of fetal death at 38 weeks ’ gestation, 
with stavudine and lamivudine (Luzzati et  al. 1999). In all cases,
the women presented aft er at least 6 months of therapy, with a 
rapidly progressive disease occurring in the 3rd trimester. Th is is in 
contrast to our case, in which the onset of the symptomatic disease 
was in the 1st trimester and only aft er 5 months of stavudine and 
lamivudine. 
 NRTI-induced lactic acidosis/hepatic steatosis have similarities 
to rare but life-threatening syndromes: acute fatty liver of preg-
nancy (AFLP) and the HELLP syndrome (haemolysis, elevated 
liver enzymes and low platelets). Data support that both of these are 
associated with a recessively inherited condition that compromises 
fatty acid oxidation. Th e same dysfunctional pathway may contrib-
ute to the development of NRTI-induced mitochondrial toxicity 
(AIDS  info 2012). In our case report, early gestational age and the 
absence of specifi c clinical and laboratory features excluded HELLP 
and AFLP. Th erefore, the diagnosis of NRTI-induced lactic acidosis 
seemed most likely. 
 Low levels of ribofl avin may also be involved in the pathogen-
esis of NRTI-induced mitochondrial toxicity (Luzzati et  al. 1999). 
Lower levels of this vitamin have been reported in pregnant women 
compared with non-pregnant women (Vir et  al. 1981). Moreover, 
ribofl avin has been used to treat lactic acidosis (Mandelbrot et  al. 
2003; Brinkman et  al. 2000). Likewise, other vitamin B complex 
elements have been used as therapeutic agents (thiamine, nicotin-
amide, pyridoxine and dexpanthenol), as well as co-enzyme Q, l-
carnitine and vitamin C (Brinkman et  al. 2000). Nevertheless, data 
in this regard is scarce to support its effi  cacy. Indeed, the treatment 
of this syndrome remains obscure and incidental. Most authors 
agree on the immediate interruption of antiretroviral drugs and the 
use of nonspecifi c adequate support measures. 
 As the benefi t of ARV prophylaxis in reducing transmission of a 
fatal infection has long been clear, and the combination of stavudine
and didanosine always seems to play a central role in the more 
serious reported cases of lactic acidosis, we decided to restart ARV 
therapy, replacing stavudine by zidovudine. Th e described derange-
ment did not recur, probably because, as happens  in vitro and 
also  in vivo, the relative potency of stavudine in inhibiting mitochon-
drial gamma DNA polymerase is higher than that of zidovudine. 
 As pregnancy may enhance HIV-infected women ’ s susceptibility 
to nucleoside analogues lactic acidosis, healthcare professionals 
should be vigilant for its onset. Nonspecifi c symptoms can easily be 
undervalued, especially in the 1st trimester. However, they may rep-
resent the initial manifestation of a life-threatening syndrome and 
hence, always require further investigation. 
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 Table I. Analytical developments throughout admission. 
D1 D2 D5 D7 D9 D11 D13 D15
AST (IU/l) 631 621 441 271 197 112 72 32
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HCO 3 (mmol/l) 12.6 12.6 17.8 17.5 17.6 16.9 20 17.9
Lactate (mg/dl) 47 38 40 45 47 43 33 31
 D, day of hospitalisation; AST, aspartate aminotransferase; ALT, alanine amino-






























































312 Obstetric Case Reports 
 Brinkman K, Vrouenraets S, Kauff man R et  al .  2000 .  Treatment of nucleoside 
reverse transcriptase inhibitor-induced lactic acidosis .  AIDS  14 : 2801 – 2802 . 
 Bristol-Myers Squibb Company .  2001 .  Healthcare provides important drug 
warning letter (5 January). 
 Fleischer  R ,  Boxwell  D ,  Sherman  KE .  2004 .  Nucleoside analogues and mito-
chondrial toxicity .  Clinical Infectious Diseases  38 : e79 – e80 . 
 Luzzati R, Del Bravo P, Di Perri G et  al .  1999 .  Ribofl avin and severe lactic 
acidosis .  Lancet  353 : 901 – 902 . 
 Mandelbrot L, Kermarrec N, Marcollet A et  al .  2003 .  Case report: nucleoside 
analogue-induced lactic acidosis in the third trimester of pregnancy .  AIDS 
 17 : 272 – 273 . 
 Sarner  L ,  Fakoya  A .  2002 .  Acute onset lactic acidosis and pancreatitis in the 
third trimester of pregnancy in HIV-1 positive women taking antiretroviral 
medication .  Sexually Transmitted Infections  78 : 58 – 59 . 
 Vir  S ,  Love  A ,  Th ompson  W .  1981 .  Ribofl avin status during pregnancy .  American 
Journal of Clinical Nutrition  34 : 2699 – 2705 . 
 Twin pregnancy with a complete 
hydatidiform mole and co-existent 
healthy fetus: Unusual case of complete 
resorption of molar pregnancy 
 S.  Dalmia 1 ,  K.  Sivakumar 1 ,  R.  Kathirvel 1 ,  K.  Phillips 1  & 
 A. M.  Coady 2 
 1 Department of Obstetrics and Gynaecology, Women and Children ’ s 
Hospital and  2 Department of Radiology, Hull Royal Infi rmary, Hull, UK 
DOI: 10.3109/01443615.2012.761187
 Correspondence: S. Dalmia, Department of Obstetrics and Gynaecology, 
Women and Children ’ s Hospital, Anlaby Road, Hull HU3 2JZ, UK. E-mail: 
sarojdalmia13@yahoo.co.in 
 Introduction 
 A twin pregnancy with a complete hydatidiform mole and a co-
existent healthy fetus (CHMF) is rare. Th e reported incidence is 1 in 
22,000 – 100,000 pregnancies (Steller et  al. 1994). Complete resorp-
tion of molar component of CHMF cases has not been reported so 
far in the literature. 
 Case report 
 A 20-year-old primigravida presented with vaginal bleeding at 10 
weeks ’ gestation. Th e ultrasound scan (USS) revealed an enlarged 
heterogenous placenta with cystic changes and a live fetus of 
approximately 11 weeks (Figure 1a). Th e initial diff erential diagno-
ses were partial mole (triploid fetus) and placental mesenchymal 
dysplasia (diploid fetus). Chorionic villous sampling (CVS) revealed 
a diploid 46XX karyotype and histopathology showed features of 
complete mole. Th e absence of p57 on immunochemical staining 
confi rmed complete mole. Th erefore a diagnosis of twin pregnancy 
with CHMF was made. Th e couple was counselled regarding the 
possible complications including miscarriage, pre-term delivery, 
intrauterine death, antepartum haemorrhage, pre-eclampsia and 
persistent gestational trophoblastic disease (PTD). Th ey opted to 
continue with the pregnancy. 
 Th e woman was seen in the antenatal clinic fortnightly with regular 
scans. All assessments were normal. USS at 16 weeks demonstrated 
a normal fetus and an enlarged placenta, mostly with marked cystic 
changes but also a smaller normal looking portion. At 19 weeks, the 
molar placenta was seen on the anterior and right side of the uterus 
and the normal placenta was posterior and to the left . Even the nor-
mal looking placenta had some cystic changes. On further scans, the 
molar placenta was seen diminishing in size (Figure 1b) and at 35 
weeks, the cystic changes were no longer visible while the normal 
looking placenta became predominant. 
 Labour was induced at 37 weeks and the woman delivered a 
healthy baby (2,845 g) vaginally. Th e placenta (20    19    2 cm, 931 g) 
was mottled with white fl ecks and patches but no cystic changes. 
Histology revealed features of 3rd trimester placenta consisting 
of haemorrhagic endovasculosis, stem and branch  villous vaso-
occlusive lesions but the molar changes seen earlier on the CVS had 
been completely reabsorbed. 
 Serial measurements of postnatal maternal serum  β -hCG dem-
onstrated a steady fall to    1 IU/L at 6 weeks. Th e woman did not 
develop PTD on a 6 months follow-up. 
 Discussion 
 When a fetus with a molar placenta is seen on USS, the diff erential 
diagnoses include a singleton gestation consisting of a partial mole 
(triploid fetus) or a CHMF, i.e. dichorionic twin gestation in which 
one twin is diploid with a normal placenta and the other twin is a com-
plete hydatidiform mole. Distinguishing partial mole from CHMF 
(by prenatal testing for fetal karyotype) is important as CHMF has a 
chance of survival. If fetal karyotype is triploid, termination of preg-
nancy can be recommended, however if it is diploid, it is not confi r-
matory diagnosis of CHMF. DNA polymorphism analysis is the most 
reliable method but routine molecular analysis is impractical. Recent 
studies have suggested that the immunohistochemical staining with 
p57 can distinguish androgenetic conceptuses (complete mole) from 
biparental ones (normal fetus, partial mole). p57 is a gene which is 
imprinted with preferential expression on the maternal allele, which 
will be absent in androgenetic conceptuses and present in biparental 
ones (Crisp et  al. 2003; Kihara et  al. 2005). 
 Although cytogenetic studies were not performed in our case, 
the presence of 46XX placental karyotype, absence of p57 on 
 immunohistochemical staining, antenatal histopathological  fi ndings 
and ultrasound demarcation between the normal and molar placenta 
 Figure 1. Ultrasonographic appearance of placenta. (a) Molar appearance of 
placenta at 11 weeks. (b) Anterior small molar placenta and posterior normal 
placenta at 34 weeks. 
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